Navigation Links
Perrigo Company Announces The Appointment Of Industry Veteran To Executive Vice President And General Manager, Rx
Date:12/4/2012

ALLEGAN, Mich., Dec. 4, 2012 /PRNewswire/ -- The Perrigo Company (Nasdaq: PRGO;TASE) today announced the appointment of Douglas Boothe as Executive Vice President and General Manager, Perrigo Pharmaceuticals, effective January 2013. Sharon Kochan, who previously held this position, has been managing the business in the interim since accepting the newly created role of Executive Vice President and General Manager, International in July 2012.

(Logo:  http://photos.prnewswire.com/prnh/20120301/DE62255LOGO)

Perrigo's Chairman, President and CEO Joseph C. Papa stated, "I am excited to welcome Doug to the Perrigo family. He brings to us more than 22 years of leadership and proven business results in the pharmaceutical and consumer industries. Doug will leverage his strategic perspective, executional leadership and industry experience in our prescription pharmaceutical business, ensuring that the strong growth and profitability we have enjoyed will continue into the future, allowing us to bring more quality, affordable products to market for patients."

Prior to joining Perrigo, Doug served as Chief Executive Officer of Actavis Inc., where he was responsible for all aspects of the company's generics business in North America and Latin America, including sales, marketing, supply chain, quality, finance, legal, IT, regulatory affairs, human resources and intellectual property. He also has served in strategic planning and business development leadership roles for Alpharma Inc., Pharmacia Corporation and Xerox Corporation. Doug has a Bachelor of Science Degree in Mechanical and Aerospace Engineering from Princeton University and a Master of Business Administration in Marketing Management and Strategic Planning from the University of Pennsylvania's Wharton School of Business.

From its beginnings as a packager of generic home remedies in 1887, Perrigo Company, based in Allegan, Michigan, has grown to become a leading global provider of quality, affordable healthcare products. The Company develops, manufactures and distributes over-the-counter ("OTC") and generic prescription ("Rx") pharmaceuticals, nutritional products and active pharmaceutical ingredients ("API") and is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. Perrigo's mission is to offer uncompromised "quality, affordable healthcare products", and it does so across a wide variety of product categories primarily in the United States, United Kingdom, Mexico, Israel and Australia, as well as certain other markets throughout the world, including Canada, China and Latin America. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 30, 2012, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Announces FDA Final Approval Of Betamethasone Valerate Foam 0.12%
2. Perrigo Company To Present At The Credit Suisse Healthcare Conference
3. Perrigo Reports Record First Quarter Revenue And Adjusted Earnings And Raises Full Year Adjusted EPS Guidance
4. Perrigo Company Announces Appointment Of New Board Of Directors Member
5. Perrigo Company To Acquire Assets Of Sergeants Pet Care Products, Inc., For $285 Million
6. Perrigo Company To Present At The Morgan Stanley Global Healthcare Conference
7. Perrigo Company Announces Quarterly Dividend
8. Perrigo Receives FDA Approval And Commences Launch Of Clobetasol Propionate Shampoo, 0.05%
9. Perrigo Company To Present At The William Blair Growth Stock Conference
10. Perrigo Announces FDA Final Approval Of Tris Pharmas Dextromethorphan Polistirex Extended-Release Oral Suspension
11. Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... Radiology has become the number one diagnostic ... spiraled to the number one ranking as a result.  ... before as the most complete and reliable method for ... back pain an MRI may confirm a suspected herniated ... in entirely different treatment protocols.  In these circumstances, patients ...
(Date:5/9/2017)...  Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ... focused on the development of oral drug delivery ... Office has granted Oramed a patent titled, "Methods ... patent covers Oramed,s invention of an oral glucagon-like ... incretin hormone that stimulates the secretion of insulin ...
(Date:5/6/2017)...   Provista , a proven leader in the supply ... announced Jim Cunniff as the company,s new president ... experience to Provista, including most recently serving as the president ... . He assumed his new role with Provista on ... for Provista," says Jody Hatcher , president, Sourcing and ...
Breaking Medicine Technology:
(Date:5/23/2017)... ... May 23, 2017 , ... Axiad IDS , ... announced CIO Applications magazine has named the company a “Top 25 Cybersecurity Companies ... the Cloud to help organizations simply and proactively address potential cybersecurity threats before they ...
(Date:5/23/2017)... N.Y. (PRWEB) , ... May 23, 2017 , ... New ... Public Health Crisis Worthy of a Policy Response”, -The Rory Staunton Foundation Calls on ... Staunton Foundation for the Prevention of Sepsis ( http://www.rorystauntonfoundation.org ) today reported on a ...
(Date:5/23/2017)... ... May 23, 2017 , ... The ... Dr. Kevin Sadati, is pleased to announce a new treatment option called Vivace ... in their face, neck, and body through a virtually pain-free, non-surgical treatment. Vivace ...
(Date:5/23/2017)... ... 2017 , ... Diagnotes, an Indianapolis-based digital healthcare communication company, ... secure clinical communication platform. The platform allows clinicians to easily escalate their preferred ... urgency of a situation. , “We know from our daily lives that ...
(Date:5/23/2017)... , ... May 23, 2017 , ... ... receive treatment using the SPEED System™ Orthodontics, with or without a referral, from ... in El Segundo, CA, who is skilled in providing patients with the ...
Breaking Medicine News(10 mins):